Breckenridge Announces Approval of its ANDA for Miglustat Capsules (generic for Zavesca®)

BERLIN, Conn., April 21, 2022 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Miglustat Capsules (generic for Zavesca^®), 100mg strength.  The product will be will be commercialized from a USA-based manufacturer.  Breckenridge plans to launch Miglustat Capsules during the third quarter of 2022 and the product will be offered in a 90-count bottle.   According to industry sales data, Zavesca and its generics had annual sales of $15 million during the twelve months ending February 2022.

About Breckenridge:
Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.
www.bpirx.com

For further information, please contact:
Breckenridge Pharmaceutical, Inc.
Robert Gasparino, Associate Vice President – Business Development
Tel: 860-828-8140
E-mail: rgasparino@bpirx.com

*All brand names and trademarks are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/breckenridge-announces-approval-of-its-anda-for-miglustat-capsules-generic-for-zavesca-301528346.html

SOURCE Breckenridge Pharmaceutical, Inc.